Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy

NCT01040000 is registered in ClinicalTrials.gov with Precision Biologics, Inc as lead sponsor.

NCT NCT01040000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01040000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy
Lead sponsor
Precision Biologics, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2012
Completion date
March 31, 2017
Enrollment
94 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer, metastatic pancreatic cancer